Core Viewpoint - WuXi AppTec (02268) has entered into a subscription agreement with its controlling shareholder WuXi Biologics (02269) to issue 24.134 million subscription shares at a price of HKD 58.85 per share, raising approximately HKD 1.42 billion [1] Group 1 - The net proceeds from the subscription are approximately HKD 1.414 billion [1] - About 90% of the proceeds will be used to further expand the group's service capabilities and production capacity, including but not limited to clinical and commercial production capacity for bioconjugated drugs, active pharmaceutical ingredients, and pharmaceuticals [1] - Approximately 10% of the proceeds will be allocated for the group's working capital needs and general corporate purposes [1] Group 2 - The subscriber is the controlling shareholder of the company, thus classified as a related party under the listing rules [1]
药明合联(02268)拟向控股股东药明生物(02269)发行2413.4万股认购股份 净筹约14.14亿港元